# A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade

> **NCT07459166** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Clear Scientific, Inc.** · enrollment: 16 (estimated)

## Conditions studied

- Fentanyl Overdose
- Fentanyl Poisoning

## Interventions

- **DRUG:** Naloxone Hydrochloride
- **DRUG:** Fentanyl
- **DRUG:** Sterile Saline
- **DRUG:** CS-1103

## Key facts

- **NCT ID:** NCT07459166
- **Lead sponsor:** Clear Scientific, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2026-07
- **Final completion:** 2026-10
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07459166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07459166, "A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07459166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*